Gastrointestinal Diseases
Show Only Open Trials
1.
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
- Study Status: Open to Enrollment
- Sponsor: Merck
- Disease Status and/or Stage: Untreated Chronic Hepatitis C
- Protocol ID: MK-5172-003 AM5
2.
SAPPHIRE-II: A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
- Study Status: Open to Enrollment
- Sponsor: Abbott
- Disease Status and/or Stage: Previously Treated Chronic Hepatitis C
3.
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
- Study Status: Open to Enrollment
- Sponsor: Hoffmann-La Roche/Genentech
- Disease Status and/or Stage: Advanced or Metastatic HER2-Positive Gastric or GEJ Cancer
- Protocol ID: BO27952
4.
A Phase Ib Study of Fractionated 90Y-hPAM4 with or without Gemcitabine in Patients with Metastatic Pancreatic Cancer who Received at Least Two Prior Treatments
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Stage IV Metastatic Pancreatic Cancer
- Protocol ID: IM-T-hPAM4-03
5.
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Gastric or Gastroesophageal (GEJ) Cancer
6.
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection (GS-US-283-0102)
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Chronic Hepatitis B
- Protocol ID: GS-US-283-0102
7.
A Study of Trastuzumab in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
- Study Status: Open to Enrollment
- Sponsor: Genentech/Roche
- Disease Status and/or Stage: Metastatic Gastric Cancer
8.
An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy
- Study Status: Open to Enrollment
- Sponsor: Bayer HealthCare
- Disease Status and/or Stage: Metastatic Colon Cancer
- Protocol ID: 15967
9.
A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa-2a and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment Naive Subjects with Chronic Hepatitis C Genotype 1b Infection
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers-Squibb
- Disease Status and/or Stage: Chronic Hepatitis C
- Protocol ID: BMS AI447-028
10.
GS-US-334-0110: A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 with Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Chronic Hepatitis C, Genotypes 1, 4, 5 or 6
- Protocol ID: GS-US-334-0110
11.
Telaprevir in Combination With Peginterferon and Ribavirin in Treatment-experienced Black/African American Subjects
- Study Status: Open to Enrollment
- Sponsor: Vertex Pharmaceuticals
- Disease Status and/or Stage: Genotype 1 Chronic Hepatitis C
- Protocol ID: VX11-950-116
12.
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg- Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C (AI444-052)
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Treatment-Naive Chronic Hepatitis C
13.
Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B
- Study Status: Open to Enrollment
- Sponsor: Gilead Sciences, Inc.
- Disease Status and/or Stage: Chronic Hepatitis B
14.
Phase II Trial of TMC435 in Combination With PSI-7977 in Prior G1 Null Responders to Peg-IFN/RBV, Hepatitis C-Infected Patients
- Study Status: Open to Enrollment
- Sponsor: Tibotec Pharmaceuticals
- Disease Status and/or Stage: Hepatitis C
15.
A Phase 2a, Pilot, Open-Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624 in Subjects With Fibrosis of the Liver
- Study Status: Open to Enrollment
- Sponsor: Gilead Sciences
- Disease Status and/or Stage: Chronic Liver Disease and Liver Fibrosis of Any Cause
16.
REO 022: A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients with Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
- Study Status: Open to Enrollment
- Sponsor: Oncolytics Biotech, Inc.
- Disease Status and/or Stage: Colon Cancer
17.
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)
18.
A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer
19.
A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors
- Study Status: Closed to Enrollment
- Sponsor: BiPar Sciences
- Disease Status and/or Stage: Metastatic Pancreatic Cancer
20.
A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.
- Study Status: Closed to Enrollment
- Sponsor: Immunomedics, Inc.
- Disease Status and/or Stage: Untreated Advanced Pancreatic Cancer
21.
Once-Daily Oral E5501 Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
- Study Status: Closed to Enrollment
- Sponsor: Eisai Inc.
- Disease Status and/or Stage: Chronic Liver Disease
22.
A MULTI-CENTER, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICSOF PSI-7977 IN COMBINATION WITH PEGYLATED INTERFERON AND RIBAVIRIN IN TREATMENT-NAÃVE PATIENTS WITH CHRONIC HCV INFECTION
- Study Status: Closed to Enrollment
- Sponsor: Pharmasset
- Disease Status and/or Stage: Chronic Hepatitis C
23.
A 3-Year, Virology Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
- Study Status: Closed to Enrollment
- Sponsor: Vertex
24.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-9190, GS-9256, Ribavirin (Copegus®), and Peginterferon Alfa 2a (Pegasys®) in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Infection
- Study Status: Closed to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Chronic Hepatitis C
25.
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
- Study Status: Closed to Enrollment
- Sponsor: Roche
- Disease Status and/or Stage: Chronic Hepatits C
26.
A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response in patients treated with DAA-containing regimens for chronic hepatitis C infection
- Study Status: Open to Enrollment
- Sponsor: Roche
- Disease Status and/or Stage: Chronic Hepatitis C
27.
Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial for the Treatment of Chronic Hepatitis C in which SCH 503034 was Administered (P05063)
- Study Status: Open to Enrollment
- Sponsor: Schering Plough Research Institute
